The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis

Autoimmunity Reviews

Volumn 10, Issue 8, 2011, Pages 482-489

  Lin, Yu Tsan ^a   Wang, Chen Ti ^a   Gershwin, M Eric ^b   Chiang, Bor Luen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoinflammatory disease; Oligo polyarticular juvenile idiopathic arthritis; Phagocytes; Regulatory T cells; Systemic juvenile idiopathic arthritis; Th17 cells

Indexed keywords

AUTOANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; GLUCOCORTICOID; HEAT SHOCK PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN S 100; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR INHIBITOR;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; CARTILAGE; CLINICAL FEATURE; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; MONOCYTE; NEUTROPHIL; PATHOGENESIS; PHAGOCYTE; POLYARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SYNOVITIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TREATMENT PLANNING; TREATMENT RESPONSE;

ADAPTIVE IMMUNITY; ARTHRITIS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOANTIGENS; CYTOKINES; HUMANS; IMMUNITY, INNATE; PHAGOCYTES; SECRETORY PATHWAY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1-TH2 BALANCE;

EID: 79957643739     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.02.001     Document Type: Review

References (118)

1. Borchers A.T., Selmi C., Cheema G., Keen C.L., Shoenfeld Y., Gershwin M.E. Juvenile idiopathic arthritis. Autoimmun Rev 2006, 5:279-298.
2. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
3. Adams D.D., Knight J.G., Ebringer A. Autoimmune diseases: solution of the environmental, immunological and genetic components with principles for immunotherapy and transplantation. Autoimmun Rev 2010, 9:525-530.
4. Berkun Y., Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010, 9:A319-A324.
5. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009, 33:3-11.
6. Invernizzi P., Gershwin M.E. The genetics of human autoimmune disease. J Autoimmun 2009, 33:290-299.
7. Kochi Y., Suzuki A., Yamada R., Yamamoto K. Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun 2009, 32:158-162.
8. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010, 34:J168-J177.
9. Tobon G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010, 35:10-14.
10. Glass D.N., Giannini E.H. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum 1999, 42:2261-2268.
11. Prahalad S. Genetics of juvenile idiopathic arthritis: an update. Curr Opin Rheumatol 2004, 16:588-594.
12. Thomson W., Donn R. Juvenile idiopathic arthritis genetics - what's new? What's next?. Arthritis Res 2002, 4:302-306.
13. Shoenfeld Y., Blank M., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases - 2008. Isr Med Assoc J 2008, 10:13-19.
14. Shoenfeld Y., Zandman-Goddard G., Stojanovich L., Cutolo M., Amital H., Levy Y., et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases - 2008. Isr Med Assoc J 2008, 10:8-12.
15. Zandman-Goddard G., Berkun Y., Barzilai O., Boaz M., Ram M., Anaya J.M., et al. Neuropsychiatric lupus and infectious triggers. Lupus 2008, 17:380-384.
16. Zandman-Goddard G., Berkun Y., Barzilai O., Boaz M., Blank M., Ram M., et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 2009, 1173:658-663.
17. Berkun Y., Zandman-Goddard G., Barzilai O., Boaz M., Sherer Y., Larida B., et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009, 18:1129-1135.
18. Angelini F., Cancrini C., Colavita M., Panei P., Concato C., Romiti M.L., et al. Role of parvovirus B19 infection in juvenile chronic arthritis. Is more investigation needed?. Clin Exp Rheumatol 2003, 21:684.
19. Chantler J.K., Tingle A.J., Petty R.E. Persistent rubella virus infection associated with chronic arthritis in children. N Engl J Med 1985, 313:1117-1123.
20. Hokynar K., Brunstein J., Soderlund-Venermo M., Kiviluoto O., Partio E.K., Konttinen Y., et al. Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue. J Gen Virol 2000, 81:1017-1025.
21. Nocton J.J., Miller L.C., Tucker L.B., Schaller J.G. Human parvovirus B19-associated arthritis in children. J Pediatr 1993, 122:186-190.
22. Ogra P.L., Chiba Y., Ogra S.S., Dzierba J.L., Herd J.K. Rubella-virus infection in juvenile rheumatoid arthritis. Lancet 1975, 1:1157-1161.
23. Pritchard M.H., Matthews N., Munro J. Antibodies to influenza A in a cluster of children with juvenile chronic arthritis. Br J Rheumatol 1988, 27:176-180.
24. Soderlund M., von Essen R., Haapasaari J., Kiistala U., Kiviluoto O., Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997, 349:1063-1065.
25. Gonzalez B., Larranaga C., Leon O., Diaz P., Miranda M., Barria M., et al. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis. J Rheumatol 2007, 34:1336-1340.
26. Oen K., Fast M., Postl B. Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada, 1975-92: cycles in incidence. J Rheumatol 1995, 22:745-750.
27. Barash J., Goldzweig O. Possible role of streptococcal infection in flares of juvenile idiopathic arthritis. Arthritis Rheum 2007, 57:877-880.
28. Henoch M.J., Batson J.W., Baum J. Psychosocial factors in juvenile rheumatoid arthritis. Arthritis Rheum 1978, 21:229-233.
29. Rimon R., Belmaker R.H., Ebstein R. Psychosomatic aspects of juvenile rheumatoid arthritis. Scand J Rheumatol 1977, 6:1-10.
30. Meyerowitz S., Jacox R.F., Hess D.W. Monozygotic twins discordant for rheumatoid arthritis: a genetic, clinical and psychological study of 8 sets. Arthritis Rheum 1968, 11:1-21.
31. Jaakkola J.J., Gissler M. Maternal smoking in pregnancy as a determinant of rheumatoid arthritis and other inflammatory polyarthropathies during the first 7years of life. Int J Epidemiol 2005, 34:664-671.
32. Tsai W.S., Yang Y.H., Wang L.C., Chiang B.L. Abrupt temperature change triggers arthralgia in patients with juvenile rheumatoid arthritis. J Microbiol Immunol Infect 2006, 39:465-470.
33. Roupe van der Voort C., Heijnen C.J., Wulffraat N., Kuis W., Kavelaars A. Stress induces increases in IL-6 production by leucocytes of patients with the chronic inflammatory disease juvenile rheumatoid arthritis: a putative role for alpha(1)-adrenergic receptors. J Neuroimmunol 2000, 11:223-229.
34. Straub R.H., Dhabhar F.S., Bijlsma J.W., Cutolo M. How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthritis Rheum 2005, 52:16-26.
35. Shoenfeld Y., Aharon-Maor A., Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol 2000, 18:181-184.
36. Aharon-Maor A., Shoenfeld Y. The good, the bad and the ugly of vaccination. Isr Med Assoc J 2000, 2:225-227.
37. Kamphuis S., Hrafnkelsdottir K., Klein M.R., de Jager W., Haverkamp M.H., van Bilsen J.H., et al. Novel self-epitopes derived from aggrecan, fibrillin, and matrix metalloproteinase-3 drive distinct autoreactive T-cell responses in juvenile idiopathic arthritis and in health. Arthritis Res Ther 2006, 8:R178.
38. Poole A.R., Ionescu M., Swan A., Dieppe P.A. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest 1994, 94:25-33.
39. Waggett A.D., Kielty C.M., Shuttleworth C.A. Microfibrillar elements in the synovial joint: presence of type VI collagen and fibrillin-containing microfibrils. Ann Rheum Dis 1993, 52:449-453.
40. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4:617-629.
41. Gattorno M., Gerloni V., Morando A., Comanducci F., Buoncompagni A., Picco P., et al. Synovial membrane expression of matrix metalloproteinases and tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002, 29:1774-1779.
42. Bywaters E.G. Pathologic aspects of juvenile chronic polyarthritis. Arthritis Rheum 1977, 20:271-276.
43. Wynne-Roberts C.R., Anderson C.H., Turano A.M., Baron M. Light- and electron-microscopic findings of juvenile rheumatoid arthritis synovium: comparison with normal juvenile synovium. Semin Arthritis Rheum 1978, 7:287-302.
44. Miossec P., van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997, 40:2105-2115.
45. Wedderburn L.R., Robinson N., Patel A., Varsani H., Woo P. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000, 43:765-774.
46. de Jager W., Hoppenreijs E.P., Wulffraat N.M., Wedderburn L.R., Kuis W., Prakken B.J. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007, 66:589-598.
47. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
48. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010, 9:785-792.
49. Nistala K., Moncrieffe H., Newton K.R., Varsani H., Hunter P., Wedderburn L.R. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008, 58:875-887.
50. Zrioual S., Toh M.L., Tournadre A., Zhou Y., Cazalis M.A., Pachot A., et al. IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 2008, 180:655-663.
51. Honorati M.C., Meliconi R., Pulsatelli L., Cane S., Frizziero L., Facchini A. High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology (Oxford) 2001, 40:522-527.
52. Chabaud M., Lubberts E., Joosten L., van Den Berg W., Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001, 3:168-177.
53. Koshy P.J., Henderson N., Logan C., Life P.F., Cawston T.E., Rowan A.D. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002, 61:704-713.
54. Lubberts E., van den Bersselaar L., Oppers-Walgreen B., Schwarzenberger P., Coenen-de Roo C.J., Kolls J.K., et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003, 170:2655-2662.
55. Chabaud M., Fossiez F., Taupin J.L., Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998, 161:409-414.
56. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
57. Katz Y., Nadiv O., Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. Arthritis Rheum 2001, 44:2176-2184.
58. Koenders M.I., Lubberts E., van de Loo F.A., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006, 176:6262-6269.
59. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52:1037-1046.
60. Langier S., Sade K., Kivity S. Regulatory T cells: the suppressor arm of the immune system. Autoimmun Rev 2010, 10:112-115.
61. Antiga E., Kretz C.C., Klembt R., Massi D., Ruland V., Stumpf C., et al. Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun 2010, 35:342-350.
62. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
63. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277-285.
64. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
65. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
66. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
67. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
68. Vukmanovic-Stejic M., Zhang Y., Cook J.E., Fletcher J.M., McQuaid A., Masters J.E., et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006, 116:2423-2433.
69. Horwitz D.A., Zheng S.G., Gray J.D. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol 2008, 29:429-435.
70. de Graeff-Meeder E.R., van Eden W., Rijkers G.T., Prakken B.J., Kuis W., Voorhorst-Ogink M.M., et al. Juvenile chronic arthritis: T cell reactivity to human HSP60 in patients with a favorable course of arthritis. J Clin Invest 1995, 95:934-940.
71. de Kleer I.M., Wedderburn L.R., Taams L.S., Patel A., Varsani H., Klein M., et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004, 172:6435-6443.
72. Cao D., van Vollenhoven R., Klareskog L., Trollmo C., Malmstrom V. CD25 bright CD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004, 6:R335-R346.
73. Rajaiah R., Moudgil K.D. Heat-shock proteins can promote as well as regulate autoimmunity. Autoimmun Rev 2009, 8:388-393.
74. Boog C.J., de Graeff-Meeder E.R., Lucassen M.A., van der Zee R., Voorhorst-Ogink M.M., van Kooten P.J., et al. Two monoclonal antibodies generated against human hsp60 show reactivity with synovial membranes of patients with juvenile chronic arthritis. J Exp Med 1992, 175:1805-1810.
75. Durai M., Huang M.N., Moudgil K.D. Self heat-shock protein 65-mediated regulation of autoimmune arthritis. J Autoimmun 2009, 33:208-213.
76. de Kleer I.M., Kamphuis S.M., Rijkers G.T., Scholtens L., Gordon G., De Jager W., et al. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum 2003, 48:2001-2010.
77. Prakken B.J., Roord S., van Kooten P.J., Wagenaar J.P., van Eden W., Albani S., et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60T cell epitope. Arthritis Rheum 2002, 46:1937-1946.
78. Prakken A.B., van Eden W., Rijkers G.T., Kuis W., Toebes E.A., de Graeff-Meeder E.R., et al. Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:1826-1832.
79. Prakken B.J., Samodal R., Le T.D., Giannoni F., Yung G.P., Scavulli J., et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004, 101:4228-4233.
80. Roord S.T., Zonneveld-Huijssoon E., Le T., Yung G.P., Koffeman E., Ronaghy A., et al. Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis. PLoS One 2006, 1:e87.
81. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
82. Denning T.L., Wang Y.C., Patel S.R., Williams I.R., Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 2007, 8:1086-1094.
83. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
84. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649.
85. Cascao R., Rosario H.S., Souto-Carneiro M.M., Fonseca J.E. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010, 9:531-535.
86. Massa M., Mazzoli F., Pignatti P., De Benedetti F., Passalia M., Viola S., et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum 2002, 46:2721-2729.
87. de Benedetti F., Meazza C., Vivarelli M., Rossi F., Pistorio A., Lamb R., et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003, 48:1398-1407.
88. Donn R., Alourfi Z., Zeggini E., Lamb R., Jury F., Lunt M., et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 2004, 50:1604-1610.
89. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376.
90. Ogilvie E.M., Fife M.S., Thompson S.D., Twine N., Tsoras M., Moroldo M., et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003, 48:3202-3206.
91. Lindsley C.B. Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 1987, 30:838-839.
92. Korematsu S., Miyahara H., Kawano T., Yamada H., Akiyoshi K., Sato K., et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine 2009, 27:5041-5042.
93. Fall N., Barnes M., Thornton S., Luyrink L., Olson J., Ilowite N.T., et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007, 56:3793-3804.
94. de Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G.R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158-1163.
95. Foell D., Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004, 50:3762-3771.
96. Foell D., Wittkowski H., Hammerschmidt I., Wulffraat N., Schmeling H., Frosch M., et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004, 50:1286-1295.
97. Frosch M., Vogl T., Seeliger S., Wulffraat N., Kuis W., Viemann D., et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003, 48:2622-2626.
98. Rammes A., Roth J., Goebeler M., Klempt M., Hartmann M., Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997, 272:9496-9502.
99. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201:1479-1486.
100. Dinarello C.A. Blocking IL-1 in systemic inflammation. J Exp Med 2005, 201:1355-1359.
101. de Benedetti F., Pignatti P., Gerloni V., Massa M., Sartirana P., Caporali R., et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997, 24:1403-1409.
102. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8:538-542.
103. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
104. Roth J., Vogl T., Sorg C., Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003, 24:155-158.
105. Viemann D., Strey A., Janning A., Jurk K., Klimmek K., Vogl T., et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 2005, 105:2955-2962.
106. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A., et al. MRP8 and MRP14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13:1042-1049.
107. Newton R.A., Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998, 160:1427-1435.
108. Viemann D., Barczyk K., Vogl T., Fischer U., Sunderkotter C., Schulze-Osthoff K., et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood 2007, 109:2453-2460.
109. Wittkowski H., Sturrock A., van Zoelen M.A., Viemann D., van der Poll T., Hoidal J.R., et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007, 35:1369-1375.
110. Avcin T., Tse S.M., Schneider R., Ngan B., Silverman E.D. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006, 148:683-686.
111. Behrens E.M., Beukelman T., Paessler M., Cron R.Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34:1133-1138.
112. Bleesing J., Prada A., Siegel D.M., Villanueva J., Olson J., Ilowite N.T., et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56:965-971.
113. Henter J.I., Elinder G., Soder O., Hansson M., Andersson B., Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991, 78:2918-2922.
114. Baldovinac V.P., Tivinnereim A.R., Harty J.T. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000, 290:1354-1358.
115. Quartier P., Taupin P., Bourdeaut F., Lemelle I., Pillet P., Bost M., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093-1101.
116. Senolt L., Vencovsky J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9:102-107.
117. Verbsky J.W., White A.J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004, 31:2071-2075.
118. Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005, 52:818-825.